Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 30acalabrutinib 15ibrutinib 13Cyclophosphamide 13Lenalidomide 12CT-P10 12zanubrutinib 9venetoclax 9Magnetic Resonance Spectroscopy 9Specimen Handling 8obinutuzumab 7Cytarabine 7Biopsy 7Bendamustine Hydrochloride 7pirtobrutinib 6glofitamab 6fludarabine 6fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Cyclosporine 5brexucabtagene autoleucel 4Whole-Body Irradiation 4Vincristine 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4Stem Cell Transplantation 3Sirolimus 3Methotrexate 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Hyaluronoglucosaminidase × 90 days × Clear all
NCT03267433 2026-05-05

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
689 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡